Palbociclib - Ibrance
Reading tools
Palbociclib (Ibrance®), which received FDA approval on 19 February 2016, is used after previous hormone treatment in HR-positive (hormone receptor), HER 2-negative (epidermal growth factor receptor) disease spread to distant tissues, in patients with breast cancer , together with fulvestrant. Likewise, in 2015 it received approval for use with letrozole in patients with HR-positive, HER 2-negative advanced breast cancer.
Palbociclib acts on cells undergoing division, preventing cell growth and proliferation by inhibiting the functioning of structures called CDK 4 and 6, which are responsible for division. Decreased blood cell counts, fatigue, anemia, nausea and baldness are among its side effects.
Was this article helpful?
Your feedback helps us improve our content.
Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.